CSOP Hang Seng Biotech ETF (03174.HK) fell 1.68% to HKD 3.504
Newtimespace News, as of 11:02 on May 8, CSOP Hang Seng Biotech ETF (03174.HK) was quoted at HKD 3.504, down 1.68%. The ETF opened at HKD 3.564, with a high of HKD 3.564 and a low of HKD 3.504. The latest NAV per unit is HKD 3.571, with a premium rate of -0.18%. The asset size is approximately HKD 906 million.
CSOP Hang Seng Biotech ETF (03174.HK) tracks the Hang Seng Biotech Index, which is compiled and published by Hang Seng Indexes Company Limited. The index aims to reflect the overall performance of biotechnology companies listed on The Stock Exchange of Hong Kong, covering enterprises in sectors such as pharmaceuticals, biotechnology, and medical equipment. As an important sector in the emerging market, the Biotech Index exhibits characteristics of both high growth and high volatility, serving as a key reference benchmark for investors seeking exposure to the healthcare sector.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- PINESTONE (00804.HK): Net Proceeds of HKD 24.2 Million from Placing for Virtual Asset Licence Application and AI Application Expansion
- MICROTECH MED-B (02235.HK): Enters Raw Material Purchase Framework Agreement with Connected Person Hangzhou Shukang
- DETAI NEWENERGY (00559.HK): Enters Memorandum of Understanding for Proposed Acquisition of HKD 505 Million; Trading Remains Suspended
- SCIENTECH (02291.HK): Acquires 54.2384% Equity of Shanghai Minwei Biotechnology for RMB 1.088 Billion, Constituting Major and Connected Transaction
- CHINAHONGQIAO (01378.HK): Revises Annual Caps under Industrial Products Purchase Agreement, 2027 Cap Raised to RMB 26.24 Million